2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - New Orleans Theatre B
Technology and Procedures, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Vaccines, Immunotherapy, Monoclonal Antibody Therapy, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, LGL, T Cell Lymphoma, Research, Clinical Research, Clinical Trials, Study Population, Human
PAPER

907 A multi-center phase I study to assess the safety, immunogenicity, and preliminary antitumor activity of the EBV mRNA vaccine (WGc-043 injection) in patients with R/R lymphoma

He Li Sr, Shu Cheng, MD2, Keshu Zhou, PhD3, Xudong Zhang, MD4, Qingqing Cai, MD5, Yuting Chen6, Jia Miao7, Yuquan Wei8, Xiangrong Song9, Ting MD, PhD Niu, MD, PhD10, Weili Zhao11
1 Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University., Chengdu, China
2 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine., Shanghai, China
3 Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital., Zhengzhou, China
4 Department of Oncology, the First Affiliated Hospital of Zhengzhou University., Zhengzhou, China
5 Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center., Guangzhou, China
6 State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University., Chengdu, China
7 Early Phase Research Ward, West China Hospital, Sichuan University., Chengdu, China
8 National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University., Chengdu, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University., Chengdu, China
9 National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University., Chengdu, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University., Chengdu, China
10 Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University., Chengdu, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University., Chengdu, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University., Chengdu, China
11 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine., Shanghai, China

Background

Epstein-Barr virus (EBV) is closely linked to the pathogenesis of various lymphomas, including EBV-associated B-cell and T/NK cell lymphomas. Notably, over 90% of NK/T cell lymphomas (NKTCL) are EBV-positive, which serves as a key driver of tumorigenesis, invasion, and progression. WGc-043, a therapeutic mRNA vaccine, shows promise against EBV-positive cancers and may provide therapeutic benefit to EBV-positive lymphoma patients by targeting EBV-driven oncogenesis. This phase I study evaluates the safety, immunogenicity, and preliminary antitumor activity of WGc-043 in patients with lymphoma (ChiCTR2500108428).

Methods

This multi-center, open-label, phase I study enrolled patients with EBV-positive relapsed or refractory (R/R) lymphoma in China. The primary inclusion criteria were patients diagnosed with R/R lymphoma refractory to standard treatment, with EBER positivity in tumor tissue confirmed by ISH or FISH assay, and an ECOG performance status of 0-2. WGc-043 was administered intramuscularly at doses ranging from 100 µg to 500 µg, including 5 doses of base immunization followed by optional personalized treatment. The primary endpoints were safety, DLT and its incidence, as well as MTD or RP2D; the secondary endpoints included ORR, DCR, DoR, PFS, pharmacokinetic, and immunogenicity.

Results

The 20 enrolled subjects consisted of patients diagnosed with NKTCL (13 pts), Hodgkin's lymphoma (4 pts), diffuse large B-cell lymphoma (2 pts), and peripheral T-cell lymphoma (1 pt). No serious adverse reactions (SARs) or dose-limiting toxicities (DLTs) were reported in any subjects receiving WGc-043 at doses ranging from 100 µg to 500 µg. A total of 95.0% (19/20) of subjects experienced treatment-related adverse events (TRAEs), all of which were grade 1 or 2, indicating good overall tolerability. The most common TRAEs were fever (17/20), injection site pain (11/20), anemia (10/20), neutropenia (8/20), leukopenia (6/20), and injection site induration (6/20). A total of 12 patients with R/R NKTCL had at least one efficacy assessment result, with ORR of 41.7% (5/12) and DCR of 58.3% (7/12); The ORR and DCR of the 300 μg dose group were 50.0% (2/4) and 50.0% (2/4), respectively. Notably, one patient in each of the 300 µg and 500 µg dose groups achieved PR after 5 doses and CR after 7 doses, demonstrating promising therapeutic potential of the vaccine.

Conclusions

WGc-043 is well tolerated with a safety profile that reflects its potential for favorable patient outcomes. The observed efficacy in the R/R NKTCL cohort suggests a promising clinical benefit. Further research is needed to confirm these findings and to explore the full potential of the vaccine in larger studies.

Ting MD, PhD Niu, MD, PhD: No relevant conflicts of interest to declare.